Evidence map›Paper›PMID 38640885›Full record

ArticleAddictive behaviors2024

Characterizing alcohol cue reactive and non-reactive individuals with alcohol use disorder.

Dylan E Kirsch, Erica N Grodin, Lara A Ray

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addictive behaviors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04249882 (A Novel Human Laboratory Model for Screening Medications for Alcohol Use Disorder), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04249882 phase2completednot on this map

A Novel Human Laboratory Model for Screening Medications for Alcohol Use Disorder

TypeinterventionalSponsorUniversity of California, Los AngelesRan2020 to 2022Enrolled53ConditionsAlcohol Use DisorderArmsPlacebo, Naltrexone, Varenicline
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Who is alcohol cue-reactive? A machine learning approach.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dylan E KirschDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095-1563, USA.
Erica N GrodinDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095-1563, USA; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Lara A RayDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095-1563, USA; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: lararay@psych.ucla.edu.
University of California, Los Angeles · US

Funding

UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
Characterizing the Microbiome-Gut-Brain Axis in Individuals with Alcohol Use DisorderK01AA029712 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Erica N Grodin · 2022 to 2026
$819k
Integrating findings across stages of medication development for AUDR21AA029771 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2021 to 2022
$438k
A clinical neuroscience approach to understand stress coping in alcohol use disorderF32AA031425 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIRSCH, DYLAN E · 2024 to 2024
$32k
NIAAA NIH HHS F32 AA031425NIAAA NIH HHS K01 AA029712NIAAA NIH HHS K24 AA025704NIAAA NIH HHS R21 AA029771NIDA NIH HHS T32 DA024635
6 · The paper itself

Abstract

purposeExposure to alcohol-related cues is thought to elicit a conditional response characterized by increased craving in individuals with alcohol use disorder (AUD). In the context of AUD research, it is important to consider that not all individuals with an AUD are alcohol cue reactive. This study systematically examined subjective alcohol cue reactivity and its clinical and drinking correlates in individuals with an AUD enrolled in a human laboratory pharmacotherapy trial.

methodsIndividuals with current moderate-to-severe AUD (N = 52) completed a standard alcohol cue exposure paradigm and individual difference assessments as part of a human laboratory pharmacotherapy trial (NCT04249882). We classified participants as cue reactive (CR+) and cue non-reactive (CR-), as indicated by self-reported, subjective alcohol urge, and examined group differences in baseline clinical characteristics and drinking outcomes over the course of the trial.

resultsTwenty participants (38%) were identified as CR+, while 32 participants (62%) were identified as CR-. The CR+ and CR- groups did not differ in baseline drinking and AUD clinical characteristics, but the groups differed in race composition (p = 0.02) and smoking prevalence (p = 0.04) such that the CR+ group had lower prevalence of smokers. The CR+, compared with the CR-, group drank more during the trial titration period (p = 0.03). Both groups reduced drinking across the trial (p's < 0.001), but the CR+ group exhibited a smaller reduction in drinking, compared with the CR- group (time x group, p = 0.029; CR-, p < 0.0001; CR+: p = 0.01).

conclusionResults indicate that cue reactivity is a heterogenous construct. Recognizing this heterogeneity, and the clinical factors associated with it, is critical to advancing this paradigm as an early efficacy marker in AUD research.

Indexed as

AlcoholismCravingCuesAdultAlcohol DeterrentsAlcohol DrinkingFemaleHumansMaleMiddle AgedAlcohol DeterrentsAlcohol drinkingAlcohol use disorderCravingCue reactivityPharmacotherapy

Identifiers

PMID38640885
PMCPMC11827589
OpenAlexW4394945676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.